Improvement in long-term prognosis of elderly patients with acute myocardial infarction after the introduction of intravenous thrombolytic therapy

Scandinavian Cardiovascular Journal

Volumn 32, Issue 6, 1998, Pages 365-370

  Madsen, Johnny Koerstz ^a   Pedersen, Flemming ^a   Nielsen, Henrik ^a   Jensen, Gunnar Vagn ^a   Hansen, Jørgen Fischer ^a  

^a HVIDOVRE HOSPITAL   (Denmark)

Author keywords

Age matched control group; AMI; Elderly; Long term survival; Thrombolysis

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANISTREPLASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIGOXIN; DIURETIC AGENT; FIBRINOLYTIC AGENT; NITRATE; STREPTOKINASE;

ACUTE HEART INFARCTION; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL ANALYSIS; SURVIVAL RATE;

EID: 0031739538     PISSN: 14017431     EISSN: None     Source Type: Journal    
DOI: 10.1080/14017439850139825     Document Type: Article

References (21)

1. AIMS Trial Study Group. Long-term effects of intravenous streptase in acute myocardial infarction: final report of AIMS study. Lancet 1990; 335: 427-431.
2. ASSET Study Group. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Lancet 1988; ii: 525-530.
3. GISSI. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; i: 397-402.
4. GUSTO-Investigators. An international randomised trial comparing four thrombolytic strategies for acute myocardial infarction. New Engl J Med 1993; 329: 673-682.
5. ISIS Collaborative Study Group. ISIS-3: a randomised comparison of streptokinase vs. tissue plasminogen activator vs. anistreplase and of aspirin plus heparin vs. aspirin alone among 41 299 cases of suspected myocardial infarction. Lancet 1992; 339: 753-770.
6. Elder AT, Fox KA. Thrombolytic treatment for elderly patients. Age is not a contraindication. Br Med J 1992; 305: 846-847.
7. Hendra TJ, Marshall AJ. Increased prescription of thrombolytic treatment to elderly patients with suspected acute myocardial infarction associated with audit. Br Med J 1992; 304: 423-425.
8. Herlitz J, Karlson BW, Hjalmarson Å. Prognosis of acute myocardial infarction in relation to age. Card in the Elderly 1993; 1: 54-61.
9. Lew AS, Hod H, Cercek B, Shah PK, Ganz W. Mortality and morbidity rates of patients older and younger than 75 years with acute myocardial infarction treated with intravenous streptokinase. Am J Cardiol 1987; 59: 1-5.
10. Pedersen F, Madsen JK, Fischer Hansen J. Clinical experiences with thrombolytic therapy in elderly patients with acute myocardial infarction.: (In press for Card in the Elderly).
11. Weaver WD, Litwin PE, Martin JS, et al. Effect of age on use of thrombolytic therapy and mortality in acute myocardial infarction. J Am Coll Cardiol 1991; 18: 657-662.
12. GISSI-2. A factorial randomised trial of alteplase vs. streptokinase and heparin vs. no heparin among 12 490 patients with acute myocardial infarction. Lancet 1990; 336: 65-71.
13. The International Study Group. In-hospital mortality and clinical course of 20 891 patients with suspected myocardial infarction randomised between alteplase and streptokinase with or without heparin. Lancet 1990; 336: 71-75.
14. Nielsen H Acute myocardial infarction in the elderly. Thesis, Copenhagen, March 1993.
15. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected myocardial infarction: ISIS-2. Lancet 1988; ii: 349-360.
16. Hjelmdahl P, Eriksson SV, Held C, Rehnquist N. Prognosis of patients with stable angina pectoris on antianginal drug therapy. Am J Cardiol 1996; 77: 6D-5D.
17. AIRE (The Acute Infarction Ramipril Efficacy) Study Group. Effect of ramipril on mortality and morbidity of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-828.
18. Køber L, Torp-Petersen C, Carlsen JE and the Trace Study Group. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995; 333: 1670-1676.
19. LATE Study Group. Late assessment of thrombolytic efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction. Lancet 1993; 342: 759-766.
20. Ohman EM, O'Connor CM, Califf RM. Role of thrombolytic therapy in the treatment of acute myocardial infarction. Card in the Elderly 1993; 1: 54-61.
21. Stevenson R, Ranjadayalan K, Wilkinson P, Roberts R, Timmis A. Short and long-term prognosis of acute myocardial infarction since introduction of thrombolysis. Br Med J 1993; 307: 349-353.